Published in Clin Investig on August 01, 1994
APC and K-ras gene mutation in aberrant crypt foci of human colon. World J Gastroenterol (2001) 0.98
Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo. Int J Oncol (2011) 0.79
Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters. J Virol (1995) 1.71
Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J Virol (1993) 1.42
Repression of the human papillomavirus type 18 enhancer by the cellular transcription factor Oct-1. J Virol (1991) 1.27
A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol (2001) 1.13
Activation of human papillomavirus type 18 E6-E7 oncogene expression by transcription factor Sp1. Nucleic Acids Res (1992) 1.12
A rapid microscale procedure for the simultaneous preparation of cytoplasmic RNA, nuclear DNA binding proteins and enzymatically active luciferase extracts. Nucleic Acids Res (1991) 1.05
Regulation of human papillomavirus transcription by the differentiation-dependent epithelial factor Epoc-1/skn-1a. J Virol (1996) 0.95
Cellular control of human papillomavirus oncogene transcription. Mol Carcinog (1994) 0.93
Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci (2007) 0.90
A novel cis-stimulatory element maps to the 5' portion of the human papillomavirus type 18 upstream regulatory region and is functionally dependent on a sequence-aberrant Sp1 binding site. J Gen Virol (1993) 0.86
Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene (2006) 0.85
Expression pattern of AP-2 transcription factors in cervical cancer cells and analysis of their influence on human papillomavirus oncogene transcription. J Mol Med (Berl) (2001) 0.81
Peptide aptamers: exchange of the thioredoxin-A scaffold by alternative platform proteins and its influence on target protein binding. Cell Mol Life Sci (2002) 0.81
Molecular mechanisms of virus-induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins. J Mol Med (Berl) (1995) 0.80
Peptide aptamers: powerful new tools for molecular medicine. J Mol Med (Berl) (2000) 0.79
Differential cell cycle response of nontumorigenic and tumorigenic human papillomavirus-positive keratinocytes towards transforming growth factor-beta1. J Mol Med (Berl) (2000) 0.78
[15 years of myocardial infarct cases at the Department of Internal Medicine of the Bonyhád Hospital and urbanization]. Orv Hetil (1980) 0.75
Peptide aptamers: new tools to study protein interactions. J Steroid Biochem Mol Biol (2001) 0.75
p53 mutations are rare events in recurrent cervical cancer. J Mol Med (Berl) (2001) 0.75
Human tumor viruses. Anticancer Res (2000) 0.75